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umerous studies have demonstrated that symptomatic patients with obstructive left main (LM) coronary artery disease (CAD), 3-vessel CAD (3VD), or 2-vessel CAD (2VD) involving the proximal left anterior descending artery (pLAD) have significantly worse prognosis and increased cardiovascular events. [1] [2] [3] In these high-risk patients, expeditious identification and revascularization have been proven to improve clinical outcomes. [4] [5] [6] [7] Decades ago, clinical predictive risk models and scores were developed to estimate pretest likelihoods for CAD, including LM CAD and 3VD. [8] [9] [10] [11] In these studies, the prevalence of LM CAD and 3VD ranged from 8% to 33% in symptomatic patients suspected of having CAD who were referred for invasive coronary angiography (ICA), far higher than is seen in current populations undergoing evaluation for suspected CAD. 12 In fact, even with current risk assessment tools and noninvasive testing, >50% of patients are found to have nonobstructive CAD at the time of their ICA. 13 Since the 1990s, when many of the prediction models were developed, the presentation, treatment, and natural history of CAD have dramatically changed. This warrants the need to reevaluate these risk predictions. The aim of this study is to develop contemporary predictive models using clinical features, risk factors, and test results from the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) to identify symptomatic outpatients with high-risk CAD before any noninvasive testing that may help to inform care decisions.
14 Secondary aims include comparing our models to older and current predictive models, as well as evaluating present-day clinical outcomes in patients identified with high-risk CAD.
METHODS
Patient Population
PROMISE was a prospective randomized trial comparing health outcomes in stable symptomatic outpatients who required further evaluation and who were randomly assigned to an initial strategy of either anatomic testing or functional testing. The study design and primary results of the PROMISE study have been previously described.
14 Local or central institutional review boards approved the trial, and all patients provided written informed consent. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. The complete data set for the PROMISE trial has been deposited with the National Institutes of Health and is publicly available (https://biolincc.nhlbi.nih.gov/studies/promise/).
From the PROMISE study, patients who were randomized to initial anatomic testing and received an interpretable coronary computed tomographic angiography (CTA) as their diagnostic test (n=4589) were identified. This study classified patients as high-risk or non-high-risk CAD according to 2 definitions based on site-read CTA results: LM coronary artery stenosis (≥50% stenosis) or either (1 15 reported that patients with multiple (>2) vessels with ≥50% stenosis on CTA demonstrated significantly worse clinical outcomes as compared to patients with <50% stenosis. If data were inadequate to determine whether a specific vessel met either high-or non-high-risk criteria (ie, uninterpretable vessel) the patient was classified as indeterminate CAD.
Cardiovascular Risk Factor Definition
Patient demographics, symptoms, and cardiovascular risk factors were collected and assessed at the time of the PROMISE study enrollment.
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Clinical Outcomes and Events
All patients in the anatomic testing (CTA) arm were followed for coronary artery interventions (ICA, percutaneous coronary intervention [PCI] , and coronary artery bypass graft surgery [CABG] ) within 90 days after their initial CTA. Also, the following adjudicated events were identified over a 26-month (median) follow-up period: unstable angina hospitalization (UAH), myocardial infarction (MI), cardiovascular death, and all-cause death.
Statistical Analysis
Demographics, symptoms, and risk factors were examined as potential predictors of high-risk CAD. Descriptive statistics for
CLINICAL PERSPECTIVE
In the outpatient clinic setting, it is often difficult to identify patients with high-risk coronary artery disease (CAD). In addition to standard patient history and physical exam, physicians often order noninvasive cardiac testing, such as a coronary computed tomographic angiography, to assess for CAD. Patients with significant CAD often undergo invasive coronary angiography and then revascularization. Using the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) study cohort randomized to computed tomographic angiography, we developed 2 predictive models to identify high-risk CAD. We provided 2 different criteria for high-risk CAD defined as LM stenosis (≥50% stenosis), and either (1 Baseline characteristics, risk factors, symptoms, and laboratory/ECG variables were used in a logistic multiple regression model to predict high-risk status. Models were developed using clinical guidance and stepwise selection methods. To help achieve parsimony, as well as good predictive accuracy, an entry and exit criterion of P<0.05 was used, and the final models were confirmed using backward selection. The baseline factors in Table 1 represent the full set of candidate predictors considered in the model selection process. A few variables, such as HDL (high-density lipoprotein), left bundle branch block, left ventricular hypertrophy, nitroglycerin, and relationship of symptoms to stress or exertion, were excluded from prediction models because of the high number of missing or unknown values. The linearity of continuous predictors was assessed using restricted cubic splines and transformed if necessary. C statistics were estimated to evaluate model discrimination. Model calibration was assessed via the Hosmer-Lemeshow goodness-offit test and graphically via calibration plots that plotted the observed proportion in the high-risk group versus the mean predicted probability of high risk in each decile of the predicted value. 17 As a method of internal validation, bootstrapping was used to estimate the optimism of the C statistic while taking into account the uncertainty of the stepwise model selection procedure in each bootstrap sample. 18, 19 The final bias-corrected C statistic was estimated by subtracting the optimism measure from the C statistic obtained from the model build sample. Optimism quantifies the bias because of the potential overfitting of the model in the sample used to derive the model. The metric expresses the difference in model performance in the sample used to derive the model compared to model performance in the underlying population. Thus adjusting for optimism provides bias-corrected C statistics that better capture the model's expected discriminatory capacity in the underlying population. 18, 19 The final models are presented with an odds ratio, 95% CI, and P value for each predictor. χ 2 tests and the Fisher exact test were used to compare 90-day interventions (ICA, PCI, and CABG) between the high-risk and non-high-risk groups. Log-rank tests were used to compare clinical outcomes (UAH, MI, cardiovascular death, and all-cause death). The final models were compared with existing risk scores using the method of DeLong to compare area under the receiver operating characteristic curve of different models in the same sample.
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RESULTS
High-Risk CAD Prevalence by CTA
Of the 4589 included patients, 301 patients (6.6%) and 111 patients (2.4%) were identified with high-risk CAD based on the definition of ≥50% LM stenosis or ≥50% stenosis or ≥70% stenosis of 3VD or 2VD involving the pLAD, respectively ( Tables III  and IV As a sensitivity analysis, the model development process was repeated using backward selection. This selection procedure produced the same models as stepwise selection. Figure 2 ). Table 2 ). 21 or mDFS (C statistic, 0.71, χ 
Processes of Care and Outcomes
Model Comparison to Other Risk Scores
DISCUSSION
In the PROMISE study, high-risk CAD, defined by ≥50% LM stenosis or (1) ≥50% stenosis or (2) ≥70% stenosis of 3VD or 2VD involving the pLAD, was identified in 6.6% and 2.4% of stable symptomatic patients undergoing cardiac CTA, respectively. Two robust models, both with good calibration, were developed predicting the presence of high-risk CAD using pretest variables, and both performed better than either the PCE or mDFS in predicting event risk or obstructive CAD, whereas the [70] model performed similar to the CONFIRM highrisk model. Patients identified with high-risk CAD experienced more frequent ICA, revascularization (PCI/ CABG), and adverse events (UAH and UAH/MI/death) than those with non-high-risk coronary anatomy. The identification of high-risk individuals may assist in clinical decision making regarding testing, referral to catheterization, and intensity of medical treatment.
The prevalence of high-risk CAD from our contemporary cohort is remarkably less than in previous studies used to create currently recommended clinical risk scores. In the CASS (Coronary Artery Surgery Study) from 1975 to 1979, 20 391 symptomatic patients suspected of CAD underwent cardiac catheterizations. In this population, LM disease and 3VD was present in 8% of women and 27% of men. 22 This prevalence is not dissimilar to the 33% of patients identified with LM disease or 3VD in the cohort used to create the Duke clinical risk score. 9 Hubbard et al, 11 who created a 5-point cardiac risk score to identify high-risk CAD, reported 31% of consecutive patients referred for cardiac catheterization had LM disease or 3VD. These previously described studies used cardiac catheterization to identify high-risk CAD, which may have introduced a selection bias. In patients with chest pain undergoing coronary CTA, Min et al 15 identified 192 out of 1127 (17%) patients with either LM disease (≥50% stenosis) or 3VD or 2VD (≥70% stenosis) with pLAD.
CONFIRM, a similar contemporary study to PROMISE, enrolled 27 125 consecutive adults referred to coronary CTA for suspected CAD from 2005 to 2009. 23 Using the definition of high-risk CAD as LM (≥50%) or 3VD or 2VD (≥70%) with pLAD, CONFIRM identified 3.6% of patients with high-risk CAD, a prevalence that is much closer to PROMISE's than reported in older studies. 24 However, CONFIRM reported a slightly higher prevalence of high-risk CAD compared with our PROMISE [70] highrisk cohort (2.4%), likely because of CONFIRM including a broad population with few restrictions. In fact, 24.7% of the CONFIRM high-risk patients were asymptomatic. Only symptomatic patients were enrolled in PROMISE. From the recent SCOT-HEART trial (Scottish Computed Tomography of the HEART), 7% of the patients from the CTA arm (n=1778) were identified with 3-vessel obstructive (>70% stenosis) CAD. The number of patients with obstructive LM CAD was not reported. 25 We developed 2 models to predict [50] and [70] high-risk CAD using clinical variables easily identified in patient's medical history. Our models had 7 clinical variables in common: family history of premature CAD, older age, male sex, lower glomerular filtration rate, DM, elevated systolic blood pressure, and angina. Smoking history was a predictor in the [50] model, whereas the [70] model included sedentary lifestyle. Since both models are completely derived from clinical variables, clinicians can obtain this information real-time during an outpatient visit and use it to help determine the need for testing. By enabling physicians to identify patients who may have high-risk CAD, our models can assist in recognizing patients who may potentially benefit from more aggressive medical treatment, closer follow-up, and consideration for early invasive catheterization.
Despite the difference in prevalence of high-risk CAD found in the population used to create the older Duke risk model compared with our study cohort, Pryor et al 9 identified similar predictors for high-risk CAD including age, sex, chest pain characteristics, DM, smoking, and hypertension, but also hyperlipidemia, peripheral or cerebral artery disease, carotid bruit, prior MI, and significant Q wave and ST-T wave changes. 9 Similar to the Duke risk model, a risk score developed by Hubbard et al 11 identified 5 variables that were independently predictive of LM or 3VD: age, typical angina, DM, male sex, and both history and electrocardiographic evidence of a prior MI. In the CORSCORE study (Coronary Risk Score), the predictive accuracy of the Duke risk model was found to be marginally higher than the Diamond-Forrester model in predicting significant 3VD. 26 However, an updated Diamond-Forrester model was recently described to better predict obstructive CAD in a contemporary cohort. 27 Both our [50] and [70] models were more predictive of high-risk CAD than the PCE and mDFS ( Figure I in the Data Supplement). In addition to both of our models outperforming the PCE and Diamond and Forrester scores, our models are more clinically applicable to a contemporary population since the data set in which both the PCE and Diamond and Forrester scores were derived originated from patients in the 1960s to 1990s.
Investigators from the CONFIRM study recently created a scoring system to predict high-risk CAD based on clinical risk factors and symptoms. Similar to the clinical variables from both our models, CONFIRM identi- fied age, sex, DM, hypertension, current smoking, chest pain symptoms, family history of CAD, hyperlipidemia, and peripheral vascular disease as independent variables associated with high-risk CAD. A comparison of our [70] model with the CONFIRM model demonstrated that both performed similarly in identifying high-risk CAD ( Figure II in the Data Supplement). Similar to both of our models, the CONFIRM clinical model demonstrated better performance than the mDFS in predicting high-risk CAD. 24 Identifying patients with high-risk CAD before diagnostic testing can help ensure that these patients receive closer follow-up or early cardiac catheterization. As demonstrated in our study, patients with high-risk CAD have a greater risk of adverse cardiovascular events (UAH/MI/death) compared with patients with nonhigh-risk CAD. The difference was especially marked for UAH (Table 2 ). Puri et al 28 followed atherosclerotic progression in patients with LM CAD using serial intravascular ultrasound and reported that the patients who suffered adverse clinical events experienced more UAH as compared to MI or death. In our study, patients with high-risk CAD required more revascularization (PCI and CABG) as compared to patients without high-risk CAD. These observations were documented in previous studies in which patients with high-risk CAD on cardiac catheterization had higher cardiovascular events and derived benefit from coronary revascularization. Min et al 15 described that pLAD, multivessel, and LM disease identified on CTA were significant predictors of all-cause death; LM (≥50% stenosis) on CTA had the worst survival (85%) at ≈2 years.
It is important to note a few limitations of our study. Although the results from our prediction models were generated from the largest contemporary evaluation of noninvasive testing among patients with stable chest pain, the prevalence of high-risk CAD was found to be small. But as previously discussed, similar contemporary studies (CONFIRM and SCOT-HEART) demonstrated a comparably low prevalence of high-risk CAD in patients suspected of CAD who were referred for coronary CTA. These recent observations of lower high-risk CAD prevalence compared with previous studies/registries and others noting a decreasing prevalence of positive noninvasive testing seem to reflect the changes in cardiovascular prevention, testing, and management practices compared with decades ago and strongly support the development of new risk scores in contemporary populations. 12 Although validation of our model with a separate external cohort could potentially strengthen the model, the only large contemporary cohort similar to our symptomatic PROMISE patients would be from the SCOT-HEART study. 25 However, as mentioned above, the SCOT-HEART investigators identified patients with significant 3VD but did not report obstructive LM CAD, so external validation with our model was unobtainable. High-risk CAD patients from our study were derived only from the CT cohort of the PROMISE study. Thus, the prevalence of high-risk CAD in the cohort randomized to initial functional testing in the PROMISE study is unknown, except in those referred to cardiac catheterization who are subject to bias. Because the PROMISE study randomized patients 1:1 to either the functional or anatomic arm, we would expect a similar prevalence of high-risk CAD in the functional testing arm. In this study, high-risk CAD was identified using CTA as opposed to the gold standard test, ICA. However, previous studies have demonstrated that CTA and ICA have similar accuracy for high-risk CAD. 32 Although the PROMISE study was designed to capture only ICAs performed within 90 days after the initial CTA, 95.6% and 97.7% of the total ICAs performed in the [50] and [70] high-risk groups, respectively, were performed within those 90 days.
CONCLUSIONS
In contemporary practice, 2.4% to 6.6% of patients without prior CAD who have stable symptoms and an indication for noninvasive cardiovascular testing have high-risk CAD by CTA. Although the prevalence of high-risk CAD is low, a limited set of readily available pretest clinical variables identifies these potentially high-risk patients and is easy to use at the time of initial consultation. Patients predicted to have high-risk CAD have more cardiovascular events and undergo more revascularizations than those without high-risk CAD. Although requiring independent validation, our findings identify patients who may benefit from more aggressive medical treatment and consideration for early cardiac catheterization.
